ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+4.74%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$485M
AUM Growth
+$485M
(-19%)
Cap. Flow
-$74.8M
Cap. Flow
% of AUM
-15.41%
Top 10 Holdings %
Top 10 Hldgs %
49.77%
Holding
309
New
41
Increased
54
Reduced
66
Closed
104
Top Buys
| 1 |
Inhibikase Therapeutics
IKT
|
$16.6M |
| 2 |
Zai Lab
ZLAB
|
$13.4M |
| 3 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
$10.1M |
| 4 |
ABVX
Abivax
ABVX
|
$7.26M |
| 5 |
AVR
Anteris Technologies Global Corp. Common Stock
AVR
|
$5.88M |
Top Sells
| 1 |
Royalty Pharma
RPRX
|
$26.7M |
| 2 |
Cytokinetics
CYTK
|
$23.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$21.1M |
| 4 |
Ascendis Pharma
ASND
|
$12.4M |
| 5 |
Immunovant
IMVT
|
$8.53M |
Sector Composition
| 1 | Healthcare | 80.2% |
| 2 | Financials | 3.47% |
| 3 | Communication Services | 1.36% |
| 4 | Utilities | 0.04% |
| 5 | Energy | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Schrodinger
SDGR
$1.44B
| $485K | 0.1% | +25,147 | New | +$485K |
|
102
Apellis Pharmaceuticals
APLS
$3.48B
| $479K | 0.1% | 15,000 -2,252 | -13% | -$71.9K |
|
103
Vir Biotechnology
VIR
$686M
| $470K | 0.09% | 64,067 -255,118 | -80% | -$1.87M |
|
104
Biogen
BIIB
$19.4B
| $466K | 0.09% | 3,045 -26,580 | -90% | -$4.06M |
|
105
Phathom Pharmaceuticals
PHAT
$864M
| $450K | 0.09% | 55,400 +55,200 | +27,600% | +$448K |
|
106
Nabors Energy Transition Corp II
NETD
| $431K | 0.09% | 39,900 -20,000 | -33% | -$216K |
|
107
Akero Therapeutics
AKRO
$3.74B
| $426K | 0.09% | 15,307 -7,700 | -33% | -$214K |
|
|
CMRX
108
DELISTED
Chimerix, Inc.
CMRX
| $425K | 0.09% | 122,236 -118,321 | -49% | -$412K |
|
109
Absci
ABSI
$357M
| $413K | 0.08% | 157,665 -848,085 | -84% | -$2.22M |
|
110
Kymera Therapeutics
KYMR
$2.95B
| $402K | 0.08% | 10,000 -1,856 | -16% | -$74.7K |
|
111
Dianthus Therapeutics
DNTH
$759M
| $385K | 0.08% | 17,683 -101,055 | -85% | -$2.2M |
|
112
Viking Therapeutics
VKTX
$3.04B
| $374K | 0.07% | 9,300 +2,200 | +31% | +$88.5K |
|
113
Moderna
MRNA
$9.37B
| $374K | 0.07% | +9,000 | New | +$374K |
|
114
Context Therapeutics
CNTX
$75.4M
| $369K | 0.07% | 351,094 -22,741 | -6% | -$23.9K |
|
115
Atea Pharmaceuticals
AVIR
$267M
| $369K | 0.07% | +110,000 | New | +$369K |
|
116
Keros Therapeutics
KROS
$618M
| $368K | 0.07% | 23,246 -421,822 | -95% | -$6.68M |
|
117
AnaptysBio
ANAB
$569M
| $361K | 0.07% | 27,301 -165,419 | -86% | -$2.19M |
|
118
VistaGen Therapeutics
VTGN
$102M
| $358K | 0.07% | 121,461 -41,617 | -26% | -$123K |
|
119
Ultragenyx Pharmaceutical
RARE
$2.89B
| $337K | 0.07% | +8,000 | New | +$337K |
|
|
JVSA
120
DELISTED
JV SPAC Acquisition Corp
JVSA
| $313K | 0.06% | 30,000 | – | – |
|
121
Taysha Gene Therapies
TSHA
$797M
| $307K | 0.06% | 177,707 -73,693 | -29% | -$127K |
|
122
Leap Therapeutics
LPTX
$12M
| $305K | 0.06% | +106,000 | New | +$305K |
|
123
Arcellx
ACLX
$3.85B
| $304K | 0.06% | 3,962 | – | – |
|
124
KalVista Pharmaceuticals
KALV
$678M
| $304K | 0.06% | 35,843 +21,700 | +153% | +$184K |
|
125
Alkermes
ALKS
$4.78B
| $293K | 0.06% | 10,188 -64,243 | -86% | -$1.85M |
|